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combined treatment are characterized by the significant cubic
trend (P = 0.00284 and P = 0.029, respectively). Changes of
miRNA-126 expression level during post-treatment follow-up
were not characterized by the definite trend and not correlated
with changes of other miRNAs expression level. It was shown
the significant correlation between miRNA-25 and miRNA-205
expression levels, but was not found the trend of these miRNAs
level changes.
Conclusion: The clinical utility of the circulating miR-19b and
miR-125b expression analysis from this study remains to be
validated in large cohorts of patients with different histological
types of tumors, at the different stage of disease and outcomes.
One of the criteria for inclusion in the group must be susceptibil-
ity and/or resistance to therapy.
The research has been carried out with support of the grant from the
Russian Science Support Foundation 14-04-01881, Post-doctorate
program in TPU.
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Background: Epithelial ovarian cancer frequently metastasizes
to the omentum, a process that requires pro-angiogenic activa-
tion of HOMECs by tumour -secreted factors in their microenvi-
ronment. We have previously shown that ovarian cancer cells
secrete a range of factors with possible roles in metastatic angio-
genesis including the lysosomal proteases cathepsin D (CD) and
cathepsin L (CL). However, the role of these proteases in ovarian
cancer metastasis to the omentum is not fully understood.
Aim: To investigate whether proliferative effects of CD and CL
are dependent on their catalytic activity in HOMECs.
To investigate the intracellular signalling kinases activated by
CD and CL.
Method: HOMEC proliferation was assessed by using a colori-
metric (WST1) assay. Potential signalling pathways were exam-
ined by phosphokinase array and ELISAs. pH experiments were
carried out examine whether the observed effects were due to
the catalytic activity of CD and CL.
Result: CD and CL (50 ng/ml) significantly increased HOMEC
proliferation to 141 ± 27% (p = 0.001, n = 50) and 151% ± 34%
(p = 0.001, n = 45) respectively vs. control (100%) 72 h post-
treatment. Inhibitors of CD and CL enzyme activity had no effect
on HOMEC proliferation and subsequent pH data suggest a non-
proteolytic mitogenic activity of these cathepsins. Both proteins
induced phosphorylation of ERK1/2, AKT and p38a to 2, 1.5
and 1.5 folds respectively relative to total levels (compared to
control).
Conclusion: CD and CL induced proliferation in HOMECs. CD
and CL may non- proteolytically contribute to pro-angiogenic
responses of the omental microvasculature. Induction of phos-
phorylation of proliferative kinases ERK1/2, AKTand p38a suggest
possible downstream signalling cascades of these proteins.
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RCC is one of the main problems in oncourology. MiRNA
expression profiles are highly specific for malignant tumors of
different locations, and can be used to detect pathological molec-
ular biomarkers and to develop the optimal treatment for each
patient. Selection of miRNAs associated with the formation and
development of malignant tumors in the kidney was performed
using computer databases miRWalk (http://www.ma.uni-hei-del-
berg.de/apps/zmf/mirwalk/) and miRBase (http://www.mir-base.
org/). Paired samples of tumor and histologically normal tissue
from 46 patients with RCC were studied. RNAwas isolated by phe-
nol–chloroform extraction and treated with RNase-free DNase
after isolation. MiRNA expression analysis was performed by
RT-qPCR using Applied Biosystems (USA) kits: TaqMan Micro-
RNA Assays, TaqMan MicroRNA Reverse Transcription Kit,
TaqMan Fast Universal PCR Master Mix (2x). RNU6B was used
as reference miRNA. Quantity alterations of 20 microRNAs (hsa-
miR-219, -203, -148a, -129, -9, -34a, -34b, -34c-3p, -127, -193a-5p,
-191, -17, -24 -2*, -339 -3p, -212, -375, -125b, -124a, -132, -137) were
determined in samples of tumor compared to normal tissue
biopsy from the kidney of each patient. It was shown that the
expression of studied miRNAs usually decreased in RCC tumors.
The largest decrease of expression was observed for miR-129,
which expression was10–350-fold reduced in 93% of the samples
(P < 0.05) with no change of expression in the remaining 7% of
cases. MiR-375 (80% of cases,10–270-fold decrease), miR-34b
(79% of cases, 10–60-fold decrease), miR-124a (70% of cases, 10–
200-fold decrease) also frequently showed reduced expression
in tumors. In addition to the aforementioned ones, it had been
shown that expression in the tumor compared with histologically
normal tissue from the same patient was significantly decreased
in more than half of the cases for miR-125b, miR-127, miR-203,
miR-34c-3p, miR-9. Despite the fact that in 50% of cases
decreased expression of miR-9 was detected, it was the only of
studied microRNA with a significant increase in the expression
in 21% of cases in 10–160 times (P < 0.05). Associations between
the expression of investigated miRNAs and gender and age were
not noted. Dealing with each miRNA alone, we could not detect
the dependence of expression alteration of 20 selected miRNAs
from the stage or degree of tumor differentiation of the studied
RCC samples. However, the analysis of the expression profile of
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20 miRNAs in complex showed that decreased expression was
observed much less frequently in the samples with a later RCC
stage than in samples with early RCC stage. For example, in a
tumor sample of a patient with stage IV (T3aN2M1) expression
was reduced only for miR-129 and miR-375 in 10 times for each
miRNA, while the expression of miR-9 was increased. In samples
with stage III expression was reduced in 2 or 4 out of the selected
20 miRNAs, in samples with stage I expression decrease was
observed for 9 out of 20 studied miRNAs. Since kidney tissue from
the same patient was taken as the control, it could be assumed
that the absence of expression decrease in studied 20 miRNAs
in tumors was due to a decrease in their expression in the sur-
rounding tissues, which eliminated the difference in the quantity
of miRNAs in tumors and surrounding tissues. An additional
experiment, in which kidney tissue from healthy donors with
no history of cancer was taken as a control, showed decreased
expression of miR-125b, miR-124a, miR-127, miR-203, miR-34c-
3p, miR-9, miR-129, miR- 34b in histologically normal tissue of
patients with RCC. There was identified a group of miRNAs out
of studied 20 ones which may be involved in the progression of
RCC, they were at least miR-129, miR-375 and miR-9. Expression
characteristics of miRNAs require further study and may be used
as biomarkers.
This work was supported by Russian Foundation for Basic Research
grant 13–04-00828.
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Background: Heparansulfate (HS) is a glycosaminoglycan pre-
sent on the cell surface and in the extracellular matrix, which
interacts with diverse signal molecules and is essential for many
physiological processes including embryonic development, cell
growth, inflammation, and blood coagulation. D-glucuronyl C5-
epimerase (GLCE) is a crucial enzyme in HS synthesis, converting
D-glucuronic acid (GlcA) to L-iduronic acid (IdoA) to increase HS
flexibility. Aberrant modification may result in wrong structure
of polysaccharide chains of HS and defects of microenvironment
associated with malignant transformation.We previously
experimentally identified the GLCE polymorphism Ile597Val. Its
localization close to the activity center of the enzyme and differ-
ent physical parameters of the involved amino acids suggest that
the polymorphism is functional. So, three different variants of
GLCE dimers with different enzymatic activity may exist in
heterozygous carriers. Bioinformatics’ search (PubMed resource)
revealed interracial variations in allele frequency distribution.
Unusual high frequency of allele G was shown for black
race (45%) compared with white race (17%). Taking into account
the increased resistance of negroid race to breast cancer, we
assume a potential involvement of the GLCE polymorphism in
breast cancer.
Aim: The estimation of effects of GLCE functional polymor-
phism A2017G (Ile597Val) on the gene expression levels in normal
and breast cancer cells and LOH in breast tumors.
Materials and methods: Breast cancer patients (n = 144.) had
histologically verified diagnoses. Blood and breast cancer tissue
samples as well as matched control tissues were collected from
each patient during surgery. Genomic DNAwas isolated by phenol
extraction. Total RNA was isolated by TRIZol, RNA quantity was
accessed by Qubit instrument with appropriate reagents and
cDNA was obtained using First Strand cDNA Synthesis kit. SNP
A2017G (rs3865014) was analyzed by Custom Real-Time SNPArray
and GLCE expression levels were determined using Taq-Man-
based Real-Time PCR (Applied Biosystems). Statistical analysis
was carried out using a Statistika 9.0 software.
Results: AA genotype carriers had a 2-fold increase in GLCE
mRNA levels in tumors compared with control surrounding
tissues (0.37 ± 0.77 versus 0.17 ± 0.16, respectively, p < 0.05). Oppo-
sitely, AG genotype carriers had a 1.5-fold decrease in GLCE mRNA
levels in tumors compared with control surrounding tissues
(0.39 ± 0.29 versus 0.58 ± 0.33, respectively, p < 0.05 ). However, in
any case,the GLCE expression in both normal tissues and breast
tumors was more active in AG genotype carriers than in AA
carriers. It is known that LOH is often associated with molecular
mechanisms of carcinogenesis, we studied this process for the
same patients. According our results, LOH was detected in about
10% of cases (5/52 patients), among which G was lost in 3 patients
and A was lost in 2 patients.
Conclusion: The obtained data show a possible association
between GLCE Ile597Val polymorphism and breast cancer,
although the nature of the association remains ambiguous.
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Malignant gliomas are fast-growing, heterogeneous and inva-
sive brain tumors strongly infiltrated by non-tumor cells. Glioma
attracts variety of immune cells, in particular microglia/
macrophages and re-program these cells into immunosuppres-
sive, tumor-supporting cells. Factors responsible for
pro-invasive macrophage polarization and shaping tumor
microenvironment in tumor-supporting manner are poorly
known. We analyzed glioma secretome using proteomical
approach and identified lactadherin (Mfge8) and osteopontin
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